Literature DB >> 21787741

Establishment of a choriocarcinoma model from immortalized normal extravillous trophoblast cells transduced with HRASV12.

Yusuke Kobayashi1, Takatsune Shimizu, Hideaki Naoe, Arisa Ueki, Joe Ishizawa, Tatsuyuki Chiyoda, Nobuyuki Onishi, Eiji Sugihara, Osamu Nagano, Kouji Banno, Shinji Kuninaka, Daisuke Aoki, Hideyuki Saya.   

Abstract

Gestational choriocarcinoma is a malignant trophoblastic tumor. The development of novel molecular-targeted therapies is needed to reduce the toxicity of current multiagent chemotherapy and to treat successfully the chemoresistant cases. The molecular mechanisms underlying choriocarcinoma tumorigenesis remain uncharacterized, however, and appropriate choriocarcinoma animal models have not yet been developed. In this study, we established a choriocarcinoma model by inoculating mice with induced-choriocarcinoma cell-1 (iC³-1) cells, generated from HTR8/SVneo human trophoblastic cells retrovirally transduced with activated H-RAS (HRASV12). The iC³-1 cells exhibited constitutive activation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways and developed into lethal tumors in all inoculated mice. Histopathological analysis revealed that the tumors consisted of two distinct types of cells, reminiscent of syncytiotrophoblasts and cytotrophoblasts, as seen in the human choriocarcinoma. The tumors expressed HLA-G and cytokeratin (trophoblast markers) and hCG (a choriocarcinoma marker). Comparative analysis of gene expression profiles between iC³-1 cells and parental HTR8/SVneo cells revealed that iC³-1 cells expressed matrix metalloproteinases, epithelial-mesenchymal transition-related genes, and SOX3 at higher levels than parental trophoblastic cells. Administration of SOX3-specific short-hairpin RNA decreased SOX3 expression and attenuated the tumorigenic activity of iC³-1 cells, suggesting that SOX3 overexpression might be critically involved in the pathogenesis of choriocarcinoma. Our murine model represents a potent new tool for studying the pathogenesis and treatment of choriocarcinoma.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21787741      PMCID: PMC3157189          DOI: 10.1016/j.ajpath.2011.05.019

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  57 in total

1.  The oncogenic potential of the high mobility group box protein Sox3.

Authors:  Y Xia; N Papalopulu; P K Vogt; J Li
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

2.  Hypermethylation of SOX2 gene in hydatidiform mole and choriocarcinoma.

Authors:  Albert S M Li; Michelle K Y Siu; HuiJuan Zhang; Esther S Y Wong; Kelvin Y K Chan; Hextan Y S Ngan; Annie N Y Cheung
Journal:  Reprod Sci       Date:  2008-09       Impact factor: 3.060

3.  Enumeration of the simian virus 40 early region elements necessary for human cell transformation.

Authors:  William C Hahn; Scott K Dessain; Mary W Brooks; Jessie E King; Brian Elenbaas; David M Sabatini; James A DeCaprio; Robert A Weinberg
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

4.  Frequent loss of imprinting of PEG1/MEST in invasive breast cancer.

Authors:  I S Pedersen; P A Dervan; D Broderick; M Harrison; N Miller; E Delany; D O'Shea; P Costello; A McGoldrick; G Keating; B Tobin; T Gorey; A McCann
Journal:  Cancer Res       Date:  1999-11-01       Impact factor: 12.701

5.  Multipoint imprinting analysis in sporadic colorectal cancers with and without microsatellite instability.

Authors:  S Nishihara; T Hayashida; K Mitsuya; T C Schulz; M Ikeguchi; N Kaibara; M Oshimura
Journal:  Int J Oncol       Date:  2000-08       Impact factor: 5.650

6.  Interleukin 11 inhibits human trophoblast invasion indicating a likely role in the decidual restraint of trophoblast invasion during placentation.

Authors:  Premila Paiva; Lois A Salamonsen; Ursula Manuelpillai; Evdokia Dimitriadis
Journal:  Biol Reprod       Date:  2008-11-05       Impact factor: 4.285

7.  Ras-MAPK signaling promotes trophectoderm formation from embryonic stem cells and mouse embryos.

Authors:  Chi-Wei Lu; Akiko Yabuuchi; Lingyi Chen; Srinivas Viswanathan; Kitai Kim; George Q Daley
Journal:  Nat Genet       Date:  2008-06-08       Impact factor: 38.330

8.  Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model.

Authors:  Haiyen E Zhau; Valerie Odero-Marah; Hui-Wen Lue; Takeo Nomura; Ruoxiang Wang; Gina Chu; Zhi-Ren Liu; Binhua P Zhou; Wen-Chin Huang; Leland W K Chung
Journal:  Clin Exp Metastasis       Date:  2008-06-06       Impact factor: 5.150

Review 9.  Treatment of gestational trophoblastic tumors.

Authors:  John R Lurain
Journal:  Curr Treat Options Oncol       Date:  2002-04

10.  Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma.

Authors:  Qi Wang; Wei He; Changdong Lu; Zhong Wang; Junsheng Wang; Karl Erik Giercksky; Jahn M Nesland; Zhenhe Suo
Journal:  Anticancer Res       Date:  2009-04       Impact factor: 2.480

View more
  4 in total

1.  Mediastinal Germ Cell Tumor Exhibiting a Discrepancy between Tumor Markers and Imaging: A Case Study.

Authors:  Kei Takenaka; Toru Mukohara; Chihoko Hirai; Yohei Funakoshi; Yukiko Nakamura; Naoko Chayahara; Masanori Toyoda; Naomi Kiyota; Tomoo Itoh; Hiroshi Yokozaki; Hironobu Minami
Journal:  Case Rep Oncol       Date:  2015-08-01

2.  Dihydromyricetin induces apoptosis in a human choriocarcinoma cell line.

Authors:  Yanzhen Zuo; Qian Xu; Yanjie Lu; Dayong Sun; Kang Wang; Yuntao Lei; Xiujun Liang; Yuhong Li
Journal:  Oncol Lett       Date:  2018-07-26       Impact factor: 2.967

3.  Serum proteome profiling reveals SOX3 as a candidate prognostic marker for gastric cancer.

Authors:  Jiajia Shen; Jing Zhai; Xinqian Wu; Guiping Xie; Lizong Shen
Journal:  J Cell Mol Med       Date:  2020-05-04       Impact factor: 5.310

4.  Establishment of HRAS(G12V) transgenic medaka as a stable tumor model for in vivo screening of anticancer drugs.

Authors:  Yuriko Matsuzaki; Haru Hosokai; Yukiyo Mizuguchi; Shoji Fukamachi; Atsushi Shimizu; Hideyuki Saya
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.